التفاصيل البيبلوغرافية
| العنوان: |
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. |
| المؤلفون: |
Alexeev, Sergey M., Khorinko, Andrey V., Mukhametshina, Guzel Z., Shelepen, Konstantin G., Burdaeva, Olga N., Kulik, Sergey A., Satheesh, Chiradoni Thugappa, Srivastava, Kirti, Vikranth, Mummaneni, Kryukov, Fedor, Paltusova, Anastasia N., Shustova, Mariya S., Ivanov, Roman A. |
| المصدر: |
BMC Cancer; 8/20/2020, Vol. 20 Issue 1, pN.PAG-N.PAG, 1p, 1 Diagram, 2 Charts, 1 Graph |
| مصطلحات موضوعية: |
CLINICAL trials, TRASTUZUMAB, HORMONE receptor positive breast cancer, PANEL analysis, BREAST tumor diagnosis, RESEARCH, BIOLOGICAL products, RESEARCH methodology, ANTINEOPLASTIC agents, CELL receptors, PHARMACOKINETICS, MEDICAL cooperation, EVALUATION research, DRUG administration, TREATMENT effectiveness, COMPARATIVE studies, RANDOMIZED controlled trials, DOSE-effect relationship in pharmacology, BLIND experiment, BREAST, PACLITAXEL, COMPUTED tomography, BREAST tumors |
| مستخلص: |
Background: BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to comparatively assess efficacy and safety of BCD-022 and reference trastuzumab in combination with paclitaxel used as the therapy of metastatic HER2(+) breast cancer. Pharmacokinetics and immunogenicity were also studied.Methods: Patients with no previous treatment for metastatic HER2(+) breast cancer were randomly assigned 1:1 to BCD-022 or reference trastuzumab and were treated with trastuzumab + paclitaxel. Therapy continued for 6 cycles of therapy (every 3 weeks), until progression of the disease or unbearable toxicity. Primary study endpoint was overall response rate. Study goal was to prove equivalent efficacy of BCD-022 and reference trastuzumab. Equivalence margins for 95% CI for difference in overall response rates were set at [- 20%; 20%].Results: In total 225 patients were enrolled into the study, 115 in BCD-022 arm and 110 in reference trastuzumab arm. Overall response rate was 49.6% in BCD-022 arm and 43.6% in reference trastuzumab arm. Limits of 95% CI for difference of overall response rates between arms were [(- 8.05)-19.89%], thus, they lied within predetermined equivalence margins [- 20%; 20%]. Profile of adverse events was similar between groups (any AEs were reported in 93.81% of patients in BCD-022 arm and 94.55% of patients in reference arm). No unexpected adverse reactions were reported throughout the study. No statistically significant differences regarding antibody occurrence rate (either BAb or NAb) was found between BCD-022 (n = 3; 2.65%) and comparator (n = 4; 3.64%). Both drug products are characterized with low occurrence rate and short life of anti-trastuzumab antibodies. Pharmacokinetics assessment after 1st and 6th study drug injection also demonstrated equivalent PK parameters by all outcome measures: AUC0-504, Сmах, Тmax, T1/2. Analysis of Ctrough did not reveal any significant inter-group differences as well.Conclusions: Thus, results of this study have demonstrated therapeutic equivalence of trastuzumab biosimilar BCD-022 and referent trastuzumab drug.Trial Registration: The trial was registered with ClinicalTrials.gov (Study Number NCT01764022 ). The date of registration was January 9, 2013. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder